Effectiveness of MiniMed 640G with SmartGuard ® System for prevention of hypoglycemia in pediatric patients with type 1 diabetes mellitus

被引:0
作者
Villafuerte Quispe, Beatriz [1 ]
Martin Frias, Maria [1 ]
Belen Roldan Martin, M. [1 ]
Yelmo Valverde, Rosa [1 ]
Angeles Alvarez Gomez, M. [1 ]
Barrio Castellanos, Raquel [1 ]
机构
[1] Hosp Univ Ramon y Cajal, Serv Pediat, Unidad Diabet Pediat, Madrid, Spain
来源
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2017年 / 64卷 / 04期
关键词
Type; 1; diabetes; Predictive low glucose suspension; Pediatric age; MiniMed; 640G-SmartGuard; NOCTURNAL HYPOGLYCEMIA; INSULIN; SUSPENSION; DURATION; REDUCTION; SAFETY; RISK;
D O I
10.1016/j.endien.2017.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction/aims: Treatment with the MiniMed 640G-SmartGuard (R) system (640G-SG, sensoraugmented insulin pump system with low predicted glucose suspension feature) has been shown to decrease risk of hypoglycemia without altering metabolic control in patients with T1DM. The study purpose was to assess the impact of 640G-SG on hipoglycemia frequency and on metabolic control in a pediatric population with T1DM. Patients/methods: A retrospective study on 21 children treated with 640G-SG. HbA1c, mean blood glucose (mg/dL), glucose variation coefficient, frequency of hypoglycemia (< 70 mg/dL) and hyperglycemia (> 180 mg/dL), daily capillary blood glucose measurements, ketosis/diabetic ketoacidosis, and severe hypoglycemic episodes were analyzed and compared before and during use of the system. Fasting blood glucose, frequency of sensor use and number and duration of system suspension events were also assessed in the last month of use of the system. Results: All patients used the system continuously (5.0 +/- 2.1 months), with a median sensor use of 92%. Significant decreases were seen in hypoglycemia frequency (10.4 +/- 5.2% to 7.6 +/- 3.3%, p = 0.044) and number of capillary blood glucose measurements (11.3 +/- 2.2 to 8.1 +/- 2.1, p < 0.001), and there was no increase in hyperglycemia frequency (p = 0.65). Mean system suspension time was 3.1 +/- 1.2 h/day (37.3% of overnight stops). Changes in HbA1c, mean blood glucose, and variation coefficient were not significant. No patient experienced diabetic ketoacidosis or severe hypoglycemia. Conclusions: The sensor-augmented pump with the predictive low glucose suspension management system, as implemented in the 640G-SG system, can help avoid risk of hypoglycemiawithout significantly affecting metabolic control or causing diabetic ketoacidosis, and decreasethe burden of additional capillary blood glucose measurements in our pediatric cohort. (C) 2017 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:198 / 203
页数:6
相关论文
共 50 条
  • [21] Gastrointestinal symptoms in pediatric patients with type 1 diabetes mellitus
    Selbuz, Suna
    Bulus, Ayse Derya
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (02) : 185 - 190
  • [22] The Effectiveness of Virtual Training on the MiniMed 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic
    Vigersky, Robert A.
    Velado, Kevin
    Zhong, Alex
    Agrawal, Pratik
    Cordero, Toni L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (02) : 104 - 109
  • [23] Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes
    Summers, Julia C.
    Briganti, Esther M.
    Fitzgerald, Zachary A.
    Lambers, Leo N. J.
    Cohen, Neale D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (08) : 423 - 429
  • [24] Association between severity of hypoglycemia and loss of heart rate variability in patients with type 1 diabetes mellitus
    Silva, Ticiana Paes
    Rolim, Luiz Clemente
    Sallum Filho, Celso
    Zimmermann, Livia M.
    Malerbi, Fernando
    Dib, Sergio Atala
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (02)
  • [25] Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of type 1 diabetes mellitus
    Berlanda, Gabriela
    Telo, Gabriela H.
    Krug, Barbara Correa
    Scheffel, Rafael Selbach
    Pasinato, Bruna
    Iorra, Fernando
    dos Reis, Joao Gabbardo
    Picon, Paulo Dornelles
    Schaan, Beatriz D.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2021, 65 (02): : 164 - 171
  • [26] Effectiveness of Predicted Low-Glucose Suspend Pump Technology in the Prevention of Hypoglycemia in People with Type 1 Diabetes Mellitus: Real-World Data Using DIA:CONN G8
    Yoo, Jee Hee
    Kim, Ji Yoon
    Kim, Jae Hyeon
    DIABETES & METABOLISM JOURNAL, 2025, 49 (01) : 144 - 149
  • [27] MiniMed™ 780G Advanced Hybrid Closed-Loop System Study in Pregnant Women with Type 1 Diabetes
    Guibert, Clara
    Amoura, Lamia
    Rakotoarisoa, Luc
    Plat, Francoise
    Sonnet, Emmanuel
    Lablanche, Sandrine
    Treglia, Clemence
    Sarde, Elisa
    Leca, Viviane
    Rimareix, Frederique
    Melki, Vincent
    Baucher, Franciane
    Betari, Bouchra
    Meyer, Laurent
    Kessler, Laurence
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (12) : 893 - 901
  • [28] Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes
    Forlenza, Gregory P.
    Pinhas-Hamiel, Orit
    Liljenquist, David R.
    Shulman, Dorothy I.
    Bailey, Timothy S.
    Bode, Bruce W.
    Wood, Michael A.
    Buckingham, Bruce A.
    Kaiserman, Kevin B.
    Shin, John
    Huang, Suiying
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (01) : 11 - 19
  • [29] The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study
    Katayama, Akihiro
    Tone, Atsuhito
    Watanabe, Mayu
    Teshigawara, Sanae
    Miyamoto, Satoshi
    Eguchi, Jun
    Nakatsuka, Atsuko
    Shikata, Kenichi
    Wada, Jun
    DIABETOLOGY INTERNATIONAL, 2020, 11 (02) : 97 - 104
  • [30] Predictors of the effectiveness of insulin pumps in patients with type 1 diabetes mellitus
    Neves, Joana Camoes
    Neves, Joao Sergio
    Neves, Celestino
    Carvalho, Davide
    ENDOCRINE, 2022, 75 (01) : 119 - 128